8-oxo-2--deoxyadenosine and Polycystic-Ovary-Syndrome

8-oxo-2--deoxyadenosine has been researched along with Polycystic-Ovary-Syndrome* in 1 studies

Trials

1 trial(s) available for 8-oxo-2--deoxyadenosine and Polycystic-Ovary-Syndrome

ArticleYear
Metformin decreases serum 8-hydroxy-2'-deoxyguanosine levels in polycystic ovary syndrome.
    Fertility and sterility, 2013, Volume: 99, Issue:2

    To learn whether metformin treatment affects oxidative stress as measured by serum concentrations of 8-hydroxy-2'-deoxyguanosine (8-OHdG).. Double-blind, randomized, placebo-controlled trial.. University outpatient clinic.. The study cohort consisted of 50 obese women (body mass index [BMI] ≥ 27 kg/m(2)) and 60 nonobese patients (BMI <27 kg/m(2)), mean age was 27.7 ± 4.0 SD years.. Randomization to receive metformin or placebo for 3 months.. Serum levels of 8-OHdG before and after medical treatment.. The levels of 8-OHdG were equal at baseline in the placebo and metformin groups. Obese women had higher baseline serum concentrations of 8-OHdG. Levels of 8-OHdG were statistically significantly reduced with metformin treatment, especially in obese patients with polycystic ovary syndrome. This study was a secondary subanalysis of a previously conducted prospective multicenter, randomized, placebo-controlled study on the effects of metformin on miscarriage, pregnancy, and miscarriage rates.. Metformin treatment, compared with placebo, statistically significantly decreased 8-OHdG levels in women with polycystic ovary syndrome.. NCT00994812.

    Topics: Adult; Biomarkers; Deoxyadenosines; Double-Blind Method; Down-Regulation; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Treatment Outcome

2013